1. Home
  2. CRML vs AUTL Comparison

CRML vs AUTL Comparison

Compare CRML & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRML
  • AUTL
  • Stock Information
  • Founded
  • CRML N/A
  • AUTL 2014
  • Country
  • CRML United States
  • AUTL United Kingdom
  • Employees
  • CRML N/A
  • AUTL N/A
  • Industry
  • CRML
  • AUTL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CRML
  • AUTL Health Care
  • Exchange
  • CRML NYSE
  • AUTL Nasdaq
  • Market Cap
  • CRML 298.8M
  • AUTL 625.4M
  • IPO Year
  • CRML N/A
  • AUTL 2018
  • Fundamental
  • Price
  • CRML $3.00
  • AUTL $2.47
  • Analyst Decision
  • CRML
  • AUTL Strong Buy
  • Analyst Count
  • CRML 0
  • AUTL 5
  • Target Price
  • CRML N/A
  • AUTL $9.32
  • AVG Volume (30 Days)
  • CRML 8.0M
  • AUTL 1.8M
  • Earning Date
  • CRML 02-01-2025
  • AUTL 08-07-2025
  • Dividend Yield
  • CRML N/A
  • AUTL N/A
  • EPS Growth
  • CRML N/A
  • AUTL N/A
  • EPS
  • CRML N/A
  • AUTL N/A
  • Revenue
  • CRML $476,979.00
  • AUTL $9,011,000.00
  • Revenue This Year
  • CRML N/A
  • AUTL $461.76
  • Revenue Next Year
  • CRML N/A
  • AUTL $112.66
  • P/E Ratio
  • CRML N/A
  • AUTL N/A
  • Revenue Growth
  • CRML 326.80
  • AUTL N/A
  • 52 Week Low
  • CRML $1.23
  • AUTL $1.11
  • 52 Week High
  • CRML $11.25
  • AUTL $5.00
  • Technical
  • Relative Strength Index (RSI)
  • CRML 55.25
  • AUTL 69.22
  • Support Level
  • CRML $2.80
  • AUTL $2.24
  • Resistance Level
  • CRML $3.34
  • AUTL $2.53
  • Average True Range (ATR)
  • CRML 0.46
  • AUTL 0.13
  • MACD
  • CRML -0.05
  • AUTL -0.00
  • Stochastic Oscillator
  • CRML 42.92
  • AUTL 88.55

About CRML CRITICAL METALS CORPORATION

Critical Metals Corp is engaged in lithium exploration in Austria. It is focused on the development of its wholly-owned Wolfsberg Lithium Project (the Wolfsberg Project) located in Carinthia, Austria.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Share on Social Networks: